Any diluent selection, preparation, temperature, aliquoting, or post-reconstitution hold conditions must be established by a qualified laboratory under a validated SOP
maximal activity of KGDC is not increased by surplus E3 because the reactions catalyzed by E3 are not rate-determining in the overall sequence of reactions at standard state conditions
In 2023 the FDA placed CJC-1295 in "Category 2" of its interim 503A bulks list, meaning it identified significant safety concerns and did not permit its use in traditional pharmacy compounding
Join our notification list to be the first to know when it's back in stock
Fogarty A, Lewis SA, Scrivener SL, Antoniak M, Pacey S, Pringle M, Britton J: Oral magnesium and vitamin C supplements in asthma: a parallel group randomized placebo controlled trial